CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cipla Quality Chemical Industries Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cipla Quality Chemical Industries Ltd
Plot 1-7
1st Ring Road, Luzira Industrial Park,
Phone: +256 312341100p:+256 312341100 KAMPALA, Uganda Ticker: CQCILCQCIL

Business Summary
CIPLA Quality Chemical Industries Limited is a Uganda-based pharmaceutical manufacturing company. The Company's principal activity is manufacturing anti-retroviral drugs (ARVs) and Artemisinin-based Combination Therapies (ACTs) to combat human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) and Malaria respectively. The Company also manufactures Hepatitis B medicines. The Company's products include anti-malarials, such as Lumartem; anti-retrovirals, such as Duovir-N, Duovir, Duomone, Efavir, Nevimune and Trioday, and Hepatitis B medicines, such as Texavir. Lumartem is a fixed dose ACT. Duovir-N is a fixed dose triple combination therapy used to treat HIV infection. Duomune is indicated in combination with at least one other antiretroviral medication for the treatment of HIV infection. Trioday is a triple fixed dose combination therapy used to treat HIV infection. Texavir is a montherapy of Tenofovir used to treat Hepatitis B.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-------

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/20193/31/2019Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman, Co-Founder EmmanuelKatongole 57 11/1/2013
Chief Executive Officer, Executive Director Nevin J.Bradford 62 11/26/2013
Chief Commercial Officer, Executive Director, Co-Founder George W.Baguma 59
12 additional Officers and Directors records available in full report.

General Information
Number of Employees: 220 (As of 12/31/2017)
Outstanding Shares: 3,651,909,200 (As of 4/9/2019)
Shareholders: 2,586
Stock Exchange: UGA
Fax Number: +256 414221319


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 15, 2019